A method for the controlled assessment of two agents for possible interaction in the treatment of endogenous depression is described. This consisted of dose-ranging the supplementary agent (oxypertine 30 mg and 60 mg daily or matching placebo) during Week 2 to Week 6 having established all patients on a therapeutic dose of imipramine during Week 1. The reported enhancement of imipramine by oxypertine was not confirmed.
Get full access to this article
View all access options for this article.
References
1.
AndenNFuxeK (1971) The influence of benzquinamide, oxypertine and prenylamine on monoamine levels and on monoamine effects in the spinal cord. Acta Pharmacologica (Kbh)30, 225.
2.
BakI JHasslerRKimJ S (1969) Differential monoamine depletion by oxypertine in nerve terminals. Zeitschrift fuer Zellforschung und Mikroskopische Anatomie (Berlin)101, 448.
3.
ForrestA DMauleM (1972) A controlled trial of oxypertine in patients with anxiety. Postgraduate Medical Journal Supplement4.48, 30.
4.
MerskeyHBuhrichH (1972) Is oxypertine an activating tranquilliser?Postgraduate Medical Journal Supplement4.48, 26.
5.
MungavinJ M (1972) A multicentre clinical trial of oxypertine in anxiety neurosis. Postgraduate Medical Journal Supplement4.48, 47.
6.
SimM (1971) Psychiatric assessment and recording. Clinical Trials Journal8, 3.
